In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d

Ann Intern Med. 2022 Apr;175(4):JC40. doi: 10.7326/J22-0017. Epub 2022 Apr 5.

Abstract

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509-20. 34914868.

Publication types

  • Comment

MeSH terms

  • Adult
  • COVID-19*
  • Cytidine / analogs & derivatives
  • Hospitalization
  • Humans
  • Hydroxylamines / adverse effects
  • SARS-CoV-2

Substances

  • Hydroxylamines
  • Cytidine
  • molnupiravir